logo-loader

Avacta Group - Exciting partnership with Bach BioSciences

Published: 17:34 30 Jul 2018 AEST

Avacta Group Plc (LON:AVACT) has recently finalised a co-development partnership with Boston-based Bach BioSciences, to exploit the potential of the Affimer platform for the development of a novel class of drug conjugates.

Executive summary

Despite the favourable reaction to the announcement of the Bach Biosciences agreement (stock up 35%), Avacta’s market capitalisation is still much lower than biotech peers  that have unique protein-based platforms and drug candidates in the clinical stage, where Avacta is on track to be by 2020.

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities,...

FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:

This document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.

Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO

FOR OUR FULL DISCLAIMER CLICK HERE

Lithium Australia and MinRes forge ahead with LieNA® pilot program

Lithium Australia Ltd (ASX:LIT, OTC:LMMFF) managing director Simon Linge discusses with Proactive’s Jonathan Jackson progress on its Mineral Resources Ltd (ASX:MIN) partnership having embarked on a pilot program for LieNA® processing technology. Linge elaborates on the joint development...

24 minutes ago